XML 15 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Net sales $ 592.1 $ 585.4
Cost of goods sold 282.7 279.4
Gross profit 309.4 306.0
Selling, general and administrative expense 212.4 208.8
Research and Development Expense 62.9 73.5
Segment profit (loss) 34.1 23.7
Interest expense 12.3 12.0
Foreign exchange (gains) losses, net (2.4) (2.7)
Marketable Securities, Unrealized (Gain) Loss 738.2 (31.8)
Other Nonoperating Income (Expense) 24.2 37.2
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (689.8) 83.4
(Provision) benefit for income taxes 162.7 (19.4)
Net income attributable to Bio-Rad $ (527.1) $ 64.0
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ (19.55) $ 2.29
Weighted average common shares - basic 26,958 27,941
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ (19.55) $ 2.29
Weighted average common shares - diluted 26,958 27,955